Public stakeholder meeting on COVID-19 vaccines and therapeutics in the EU

• Date:
  Thursday, 25 November 2021 , 13:00 - 15:15 Amsterdam time (CET)
• Location:
  Online
  European Medicines Agency, Amsterdam, the Netherlands
• Twitter:
  Public stakeholder meeting on COVID-19 vaccines and therapeutics in the EU

Slido: #EMAPublicMeeting4

Event summary

This fourth public meeting will provide an update on COVID-19 vaccines and therapeutics in the EU. It will also address misinformation and highlight the current vaccination coverage in the EU.

The following topics will be covered:

• COVID-19 therapeutics and vaccines in the EU, including vaccine effectiveness, and the use of booster and third doses in national vaccination campaigns;
• Update on vaccine safety information;
• COVID-19 epidemiological situation and vaccination coverage in the EU;
• Misinformation on COVID-19 vaccines.

The event will also allow the public and stakeholders to further inform EMA of their needs, expectations and any concerns.

Documents

Agenda - Public stakeholder meeting on COVID-19 vaccines and therapeutics in the EU

Presentation - Update on approved and candidate COVID-19 vaccines and therapeutics (M. Cavaleri, EMA)

Presentation - Update on vaccine safety monitoring (G. Genov, EMA)

Presentation - COVID-19 surveillance and vaccination coverage in the EU (P. Kramarz, ECDC)

Presentation - Addressing misinformation on COVID-19 vaccines (M. Carr, EMA)

Video recordings

Full video recording

Update on approved and candidate COVID-19 vaccines and therapeutics, Marco Cavaleri (EMA)

Update on vaccine safety monitoring, Georgy Genov (EMA)

COVID-19 surveillance and vaccination coverage in the EU, Piotr Kramarz (ECDC)

Addressing misinformation on COVID-19 vaccines, Melanie Carr (EMA)

Registration

Registration is now closed.

No registration is required for those wishing to follow the live broadcast on EMA’s website.

For more information on how the Agency collects and uses personal data for purposes related to meetings and events, please refer to European Medicines Agency's privacy statement for the organisation of meetings and events.